| Literature DB >> 26437034 |
Claudine Piérard-Franchimont1,2, Trinh Hermanns-Lê2, Philippe Paquet2, Michael Herfs3, Philippe Delvenne2,3,4, Gérald E Piérard1.
Abstract
Basal cell carcinomas (BCCs) are the most frequent human cancer. Over 90% of all BCCs have a mutation in PTCH1 or smoothened, two conducting proteins of the Hedgehog pathway. They rarely progress deeply and metastasize; however, if they do, these advanced basal cell carcinoma become amenable to treatment by inhibiting the Hedgehog and the P13K-mTOR pathways. Such innovative drugs include vismodegib, cyclopamine, itraconazole, everolimus and a few other agents that are in early clinical development.Entities:
Keywords: Desert Hedgehog; EGF; Hedgehog; Indian Hedgehog; NF-κB; PTCH1; SMO; Sonic Hedgehog; TGF; basal cell carcinoma; cancer stem cell; cyclopamine; cytotoxic chemotherapy; everolimus; hereditary basal cell nevus syndrome; itraconazole; metastasis; protein kinase; therapy resistance; vismodegib
Mesh：
Substances：
Year: 2015 PMID： 26437034 DOI： 10.2217/fon.15.181
Source DB: PubMed Journal: Future Oncol ISSN： 1479-6694 Impact factor: 3.404